An estimated 1 million cases of breast cancer are diagnosed annually worldwide. Of these, more than 170,000 are described as triple-negative. Triple-negative breast cancer (TNBC) is defined by the lack of protein expression of estrogen receptor (ER) and progesterone receptor (PR) and the absence of HER2 protein overexpression. TNBC is a subtype of breast cancer that overlaps with the “basal-like” breast cancer. TNBC has significant clinical implications.
Methods
The epidemiology, diagnosis, clinical course, prognosis, and pathology of this subtype of breast cancer are reviewed. The authors compare the “triple-negative” and “basal-like” definitions of breast cancer. A discussion of both standard and experimental treatments for TNBC is included.
Results
The poor prognosis of high-grade TNBC relates to poor disease-free interval in the adjuvant setting, shortened progression-free survival in the metastatic setting, and the lack of targeted therapy. However, not all TNBCs are associated with a poor prognosis.
Conclusions
Although chemotherapy is the main current treatment of this subtype of breast cancer, new agents such as PARP inhibitors, which show promise in the treatment of TNBC, are currently in clinical trials.
References
1.
JemalA., SiegelR., WardE.. Cancer statistics, 2009.CA Cancer J Clin.2009; 59(4): 225–249.
2.
KaplanH.G., MalmgrenJ.A., AtwoodM.K.. Impact of triple negative phenotype on breast cancer prognosis. Poster presented at: 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, TX.
3.
AndersC.K., CareyL.A.. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.Clin Breast Cancer.2009; 9(suppl 2): S73–S81.
4.
RakhaE.A., Reis-FilhoJ.S., EllisI.O.. Basal-like breast cancer: a critical review.J Clin Oncol.2008; 26(15): 2568–2581.
5.
CareyL.A., PerouC.M., LivasyC.A.. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.JAMA.2006; 295(21): 2492–2502.
6.
LakhaniS.R., Van De VijverM.J., JacquemierJ.. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.J Clin Oncol.2002; 20(9): 2310–2318.
7.
SorlieT., TibshiraniR., ParkerJ.. Repeated observation of breast tumor subtypes in independent gene expression data sets.Proc Natl Acad Sci U S A.2003; 100(14): 8418–8423.
8.
PerouC.M., SørlieT., EisenM.B.. Molecular portraits of human breast tumours.Nature.2000; 406(6797): 747–752.
9.
SørlieT., PerouC.M., FanC.. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer.Mol Cancer Ther.2006; 5(11): 2914–2918.
10.
SørlieT., PerouC.M., TibshiraniR.. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Natl Acad Sci U S A.2001; 98(19): 10869–10874.
11.
SørlieT., WangY., XiaoC.. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.BMC Genomics.2006; 7: 127.
12.
RakhaE.A., El-SayedM.E., GreenA.R.. Prognostic markers in triple-negative breast cancer.Cancer.2007; 109(1): 25–32.
13.
SotiriouC., PusztaiL.. Gene-expression signatures in breast cancer.N Engl J Med.2009; 360(8): 790–800.
14.
KorschingE., JeffreyS.S., MeinerzW.. Basal carcinoma of the breast revisited: an old entity with new interpretations.J Clin Pathol.2008; 61(5): 553–560.
15.
MallonE., OsinP., NasiriN.. The basic pathology of human breast cancer.J Mammary Gland Biol Neoplasia.2000; 5(2): 139–163.
16.
De GiorgiU., RostiG., FrassinetiL.. High-dose chemotherapy for triple negative breast cancer.Ann Oncol.2007; 18(1): 202–203.
17.
KaplanH.G., MalmgrenJ.A., AtwoodM.K.. T1N0 triple negative breast cancer: adjuvant chemotherapy treatment and risk of recurrence. Presented at the 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, TX. Abstract 3070.
18.
CareyL.A., DeesE.C., SawyerL.. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.Clin Cancer Res.2007; 13(8): 2329–2334.
19.
LiedtkeC., MazouniC., HessK.R.. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.J Clin Oncol.2008; 26(8): 1275–1281.
20.
HeitzF., HarterP., TrautA.. Cerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumors. Presented at the 44th Annual American Society of Clinical Oncology Meeting; May 30-June 3, 2008; Chicago, IL.J Clin Oncol.2008; 26: (May 20 suppl). Abstract 1010.
21.
KaplanH.G., MalmgrenJ.A., AtwoodM.. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy.Breast J.2009; 15(5): 454–460.
22.
MillerK., WangM., GralowJ.. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.N Engl J Med.2007; 357(26): 2666–2676.
23.
SiziopikouK.P., CobleighM.. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies.Breast.2007; 16(1): 104–107.
24.
RottenbergS., JaspersJ.E., KersbergenA.. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.Proc Natl Acad Sci U S A.2008; 105(44): 17079–17084.
25.
FarmerH., McCabeN., LordC.J.. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.Nature.2005; 434(7035): 917–921.
26.
O'ShaughnessyJ., OsborneC., PippenJ.. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. Presented at the 45th Annual American Society of Clinical Oncology Meeting; May 29-June 2, 2009; Orlando, FL.J Clin Oncol.2009; 27: 18s(suppl). Abstract 3.
